Results 21 to 30 of about 9,572 (201)

Therapeutic difficulties in a patient with Ehlers-Danlos syndrome and numerous symptomatic premature ventricular contractions—case report and literature review

Frontiers in Cardiovascular Medicine, 2023
A 28-year-old female patient diagnosed with Ehlers-Danlos syndrome type III (hypermobile EDS, hEDS) was admitted to the cardiology clinic due to a 3-year history of symptomatic ventricular arrhythmia in the form of multiple premature ventricular ...
Grzegorz Sławiński, Grzegorz Sławiński, Elżbieta Wabich, Maja Hawryszko, Ludmiła Daniłowicz-Szymanowicz, Philippe Chevalier   +5 more
doaj   +1 more source

Flecainide reduces ventricular arrhythmias via a mechanism that differs from that of β-blockers in catecholaminergic polymorphic ventricular tachycardia

Journal of Arrhythmia, 2013
Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by episodic ventricular tachycardia induced by adrenergic stress.
Kenichi Dochi, Hiroshi Watanabe, Mihoko Kawamura, Akashi Miyamoto, Tomoya Ozawa, Yuko Nakazawa, Takashi Ashihara, Seiko Ohno, Hideki Hayashi, Makoto Ito, Hisanori Sakazaki, Hiro Kawata, Hiroya Ushinohama, Richard H. Kaszynski, Tohru Minamino, Naokata Sumitomo, Wataru Shimizu, Minoru Horie   +17 more
doaj   +1 more source

The Unpaceable Heart

JACC: Case Reports, 2020
This is a case of flecainide toxicity in a patient with a permanent pacemaker. This case not only highlights the effects of flecainide toxicity on surface electrocardiography but how toxicity effects pacemaker function and its ability to transvenously ...
James Nadel, MBBS, MMed, Gayathri Kumarasinghe, PhD, Rajesh Subbiah, PhD   +2 more
doaj   +1 more source

Flecainide Improve Sepsis Induced Acute Lung Injury by Controlling Inflammatory Response [PDF]

Korean Journal of Critical Care Medicine, 2016
Background: Flecainide is an antiarrhythmic agent that is used primarily in the treatment of cardiac arrhythmias. Some evidences also suggest that flecainide can participate in alveolar fluid clearance and inflammatory responses.
Jia Song, Young joong Suh, Hyun jung Lee, Eun a Jang, Hong-beom Bae, Sang-Hyun Kwak   +5 more
doaj   +1 more source

Flecainide in clinical practice

Cardiology Journal, 2023
Flecainide, similar to encainide and propafenone, is IC class antiarrhythmic, inhibiting Nav1.5 sodium channels in heart muscle cells and modulates cardiac conduction. Despite its over 40-year presence in clinical practice, strong evidence and well-known
Mikołaj Basza, Cezary Maciejewski, Wojciech Bojanowicz, Paweł Balsam, Marcin Grabowski, Przemysław Mitkowski, Maciej Kempa, Oskar Kowalski, Zbigniew Kalarus, Miłosz Jaguszewski, Andrzej Lubiński, Ludmiła Daniłowicz-Szymanowicz, Łukasz Szumowski, Maciej Sterliński, Łukasz Kołtowski   +14 more
doaj   +1 more source

Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study

Therapeutic Advances in Cardiovascular Disease, 2020
Introduction: Current atrial fibrillation (AF) guidelines recommend flecainide as a first-line rhythm control option in patients without structural heart disease. While there is proven efficacy in clinical trials and guideline support, it is hypothesized
Mikayla Muzzey, Katie B. Tellor, Karthik Ramaswamy, Martin Schwarze, Anastasia L. Armbruster   +4 more
doaj   +1 more source

Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients

Frontiers in Pharmacology, 2020
The prolongation of the QT interval represents the main feature of the long QT syndrome (LQTS), a life-threatening genetic disease. The heterozygous SCN5A V411M mutation of the human sodium channel leads to a LQTS type 3 with severe proarrhythmic effects
Jordi Cano, Esther Zorio, Esther Zorio, Andrea Mazzanti, Andrea Mazzanti, Miguel Ángel Arnau, Beatriz Trenor, Silvia G. Priori, Silvia G. Priori, Javier Saiz, Lucia Romero   +10 more
doaj   +1 more source

Flecainide-Associated Cardiogenic Shock in a Patient with Atrial Fibrillation

Case Reports in Cardiology, 2019
Flecainide is a frequently used antiarrhythmic drug, recommended by current guidelines as a first-line treatment option for restoring and maintaining sinus rhythm in patients with atrial fibrillation and no significant structural heart disease.
Erind Gjermeni, Andreas Bollmann, Gerhard Hindricks, Andreas Müssigbrodt   +3 more
doaj   +1 more source

Brugada pattern masquerading as ST-segment elevation myocardial infarction in flecainide toxicity

Indian Heart Journal, 2012
Flecainide (a class 1c antiarrhythmic) produces a dose-dependent decrease in intracardiac conduction. Its well known common electrocardiographic effects are prolongation of PR and QT intervals and the QRS complex duration.
Lovely Chhabra, David H. Spodick
doaj   +1 more source

Efficacy and Safety of Various First-Line Therapeutic Strategies for Fetal Tachycardias: A Network Meta-Analysis and Systematic Review

Frontiers in Pharmacology, 2022
Background: Fetal arrhythmias are common cardiac abnormalities associated with high mortality due to ventricular dysfunction and heart failure, particularly when accompanied by hydrops.
Jiangwei Qin, Zhengrong Deng, Changqing Tang, Yunfan Zhang, Ruolan Hu, Jiawen Li, Yimin Hua, Yifei Li   +7 more
doaj   +1 more source